Oculis Holding AG (OCS) Debt to Equity (2021 - 2022)
Oculis Holding AG (OCS) recorded quarterly Debt to Equity of -$1.25 in Q4 2022, up 32.89% quarter-over-quarter from -$1.86 in Q4 2021, and up 32.89% on a YoY basis from -$0.94 in Q4 2021.
Oculis Holding AG (OCS) Debt to Equity (2021 - 2022) Analysis & Trends
Oculis Holding AG's Debt to Equity history runs 2 years deep, the most recent figure standing at -$1.25 for Q4 2022.
- In Q4 2022, Debt to Equity rose 32.89% year-over-year to -$1.25; the TTM figure through Dec 2022 stood at -$1.25 (up 32.89% YoY), while the FY2022 annual figure was -$1.25, up 32.89% from the prior year.
- Debt to Equity was -$1.25 for Q4 2022 at Oculis Holding AG, up from -$1.86 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of -$1.25 in Q4 2022 to a low of -$1.86 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -1.25 |
| Dec 31, 2021 | -1.86 |